BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37189151)

  • 1. A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma.
    Garinet S; Didelot A; Marisa L; Beinse G; Sroussi M; Le Pimpec-Barthes F; Fabre E; Gibault L; Laurent-Puig P; Mouillet-Richard S; Legras A; Blons H
    J Transl Med; 2023 May; 21(1):324. PubMed ID: 37189151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
    Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
    Front Immunol; 2022; 13():950001. PubMed ID: 36091041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD.
    Zhao Z; Yin W; Peng X; Cai Q; He B; Shi S; Peng W; Tu G; Li Y; Li D; Tao Y; Peng M; Wang X; Yu F
    Front Immunol; 2022; 13():872387. PubMed ID: 35693786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An
    Han Y; Wong FC; Wang D; Kahlert C
    Cancer Inform; 2022; 21():11769351221100727. PubMed ID: 35645555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment.
    Chen J; Fu Y; Hu J; He J
    Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of molecular subtype and prognostic signature for lung adenocarcinoma based on neutrophil extracellular traps.
    Zuo Y; Leng G; Leng P
    Pathol Oncol Res; 2023; 29():1610899. PubMed ID: 37143472
    [No Abstract]   [Full Text] [Related]  

  • 13. Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma.
    Yang J; Luo G; Li C; Zhao Z; Ju S; Li Q; Chen Z; Ding C; Tong X; Zhao J
    BMC Cancer; 2022 May; 22(1):589. PubMed ID: 35637432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
    Li Q; Tang Y; Wang T; Zhu J; Zhou Y; Shi J
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):307-323. PubMed ID: 36575346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tumor microenvironment-related mRNA-ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma.
    Gao Z; Han H; Zhao Y; Yuan H; Zheng S; Zhang Y; Chen H
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3195-3209. PubMed ID: 34291356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A ferroptosis-related gene signature predicts overall survival in patients with lung adenocarcinoma.
    Gao X; Tang M; Tian S; Li J; Liu W
    Future Oncol; 2021 Apr; 17(12):1533-1544. PubMed ID: 33432837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma.
    Li X; Shi Y; Yin Z; Xue X; Zhou B
    J Transl Med; 2014 Jun; 12():159. PubMed ID: 24893932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
    Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
    Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.